Hanaki H, Kuwahara-Arai K, Boyle-Vavra S, Daum R S, Labischinski H, Hiramatsu K
Department of Bacteriology, Juntendo University, Tokyo, Japan.
J Antimicrob Chemother. 1998 Aug;42(2):199-209. doi: 10.1093/jac/42.2.199.
We have previously reported methicillin-resistant Staphylococcus aureus clinical strains, Mu50 and Mu3, representing two categories of vancomycin resistance: Mu50 representing vancomycin-resistant S. aureus (VRSA) with MICs > or = 8 mg/L, and Mu3 representing hetero-VRSA with MICs < or = 4 mg/L using standard MIC determination methods. The mechanisms of vancomycin resistance in these strains were investigated. These strains did not carry the enterococcal vancomycin-resistance genes, vanA, vanB, or vanC1-3, as tested by PCR using specific primers. However, both strains produced three to five times the amount of penicillin-binding proteins (PBPs) 2 and 2' when compared with vancomycin-susceptible S. aureus control strains with or without methicillin resistance; the amounts of PBP2 produced in Mu3 and Mu50 were comparable to those in the vancomycin-resistant S. aureus mutant strains selected in vitro. Incorporation of 14C-labelled Nacetyl-glucosamine into the cell was three to 20 times increased in Mu50 and Mu3, and release of the radioactive cell wall material was increased in Mu3 (and also in Mu50, though to a lesser extent), compared with control strains. The amounts of intracellular murein monomer precursor in these strains were three to eight times greater than those found in control strains. Transmission electron microscopy showed a doubling in the cell wall thickness in Mu50 compared with the control strains. Mu3 did not show obvious cell wall thickening. These data indicate that activated synthesis and an increased rate of cell wall turnover are common features of Mu3 and Mu50 and may be the prerequisite for the expression of vancomycin resistance in S. aureus.
我们之前报道过耐甲氧西林金黄色葡萄球菌临床菌株Mu50和Mu3,它们代表了两类万古霉素耐药性:Mu50代表万古霉素耐药金黄色葡萄球菌(VRSA),其最低抑菌浓度(MIC)≥8mg/L;Mu3代表异质性VRSA,使用标准MIC测定方法时其MIC≤4mg/L。对这些菌株中万古霉素耐药的机制进行了研究。通过使用特异性引物进行PCR检测,这些菌株未携带肠球菌万古霉素耐药基因vanA、vanB或vanC1 - 3。然而,与有或没有耐甲氧西林的万古霉素敏感金黄色葡萄球菌对照菌株相比,这两种菌株产生的青霉素结合蛋白(PBPs)2和2'的量是其三至五倍;Mu3和Mu50中产生的PBP2的量与体外选择的万古霉素耐药金黄色葡萄球菌突变菌株中的量相当。与对照菌株相比,Mu50和Mu3中14C标记的N - 乙酰葡糖胺掺入细胞的量增加了三至二十倍,Mu3中放射性细胞壁物质的释放增加(Mu50中也增加,尽管程度较小)。这些菌株中细胞内胞壁质单体前体的量比对照菌株中发现的量大三至八倍。透射电子显微镜显示,与对照菌株相比,Mu50的细胞壁厚度增加了一倍。Mu3未显示出明显的细胞壁增厚。这些数据表明,活化合成和细胞壁周转速率增加是Mu3和Mu50的共同特征,可能是金黄色葡萄球菌中万古霉素耐药性表达的先决条件。